Do Oral GLP-1s Work as Well as Injections? What the Clinical Data Shows
The short answer: the best oral options come close to injectable semaglutide, but injectable tirzepatide still leads the entire category, and not every oral product is competing at the same level. Here's the actual trial data, cited by name, so you can see exactly what "close" means.
| Trial (Drug) | Route | Weight Loss | Duration |
|---|---|---|---|
| SURMOUNT-1 (Tirzepatide, 15mg) | Injectable | 22.5% (efficacy estimand) | 72 weeks |
| STEP 1 (Semaglutide 2.4mg) | Injectable | 14.9–16.9% | 68 weeks |
| OASIS 1 (Oral Semaglutide 50mg) | Oral, SNAC tablet | 15.1% (treatment-policy) | 68 weeks |
| OASIS 4 (Oral Semaglutide 25mg / Wegovy Pill) | Oral, SNAC tablet | 13.6% (treatment-policy) / 16.6% (full adherence) | 64 weeks |
| ATTAIN-1 (Orforglipron / Foundayo, 36mg) | Oral, small-molecule | 11.2% (NEJM efficacy estimand) | 72 weeks |
| PIONEER PLUS (Rybelsus, 25mg, T2D pop.) | Oral, SNAC tablet | 7.0% (trial-product) | 68 weeks |
The Injectable Benchmarks
Injectable tirzepatide (Zepbound) remains the single most effective GLP-1-class option published to date: SURMOUNT-1 showed 22.5% mean weight loss at the 15mg dose using the efficacy estimand (the number reflecting full adherence to treatment), against 3.1% for placebo. Injectable semaglutide (Wegovy) posted 14.9% (treatment-policy) to 16.9% (trial-product) in STEP 1 — strong, but tirzepatide's dual GIP/GLP-1 mechanism has consistently outperformed it, including in the direct head-to-head SURMOUNT-5 trial (20.2% for tirzepatide vs. 13.7% for semaglutide over 72 weeks).
Oral Semaglutide: Genuinely Close to Injectable, at the Right Dose
This is the headline finding from the OASIS program, and it's a real one: at high enough doses, SNAC-enabled oral semaglutide gets remarkably close to the injectable pen. OASIS 1 (50mg oral) posted 15.1% weight loss using the treatment-policy estimand — essentially matching STEP 1's injectable result. OASIS 4, the trial behind the approved Wegovy pill (25mg), showed 13.6% using the same conservative estimand, or 16.6% among patients who stayed fully adherent through 64 weeks per Novo's own reporting.
The catch is dose and adherence dependency. These results come from the higher end of the oral dosing range, and the strict administration rules (empty stomach, ≤4oz water, 30-minute wait) mean real-world adherence matters more for the pill than for a once-weekly injection you can't forget to take incorrectly in the same way.
Rybelsus: A Different Trial Population, a Smaller Effect
It's worth being precise here: Rybelsus's own PIONEER trials weren't designed to test weight loss as the primary outcome — they were type 2 diabetes trials where weight was a secondary measure, often in a mixed diabetic/non-diabetic population and at lower doses than OASIS used. PIONEER PLUS showed 7.0% weight loss at the trial-product estimand for 25mg. That's meaningfully less than the Wegovy pill's OASIS 4 results, even though both are oral semaglutide — the difference comes down to dose, trial population, and endpoint design, not just format.
Foundayo: Strong, Though Not Quite at Oral Semaglutide's Ceiling
ATTAIN-1 showed orforglipron (Foundayo) producing 11.2% weight loss at the highest tested dose (36mg) using the NEJM's efficacy estimand, against 2.1% for placebo — a real, clinically meaningful result, and enough to make it the fastest-approved new molecular entity in over two decades. It currently sits a bit below OASIS's oral semaglutide numbers and further below injectable tirzepatide, though it's the only oral option without SNAC's dosing restrictions, which may translate to better real-world adherence than the trial numbers alone suggest.
Note: Lilly's own press materials cited a slightly higher 12.4% figure for the 36mg dose using a different statistical estimand than the NEJM publication’s 11.2% — both describe the same trial, just counted differently.
Compounded Oral Options: No Comparable Trial Data Exists
None of the compounded sublingual, dissolvable-tablet, or gummy products on this page have published a Phase 3 (or any controlled human) efficacy trial. That's not a knock on any individual provider so much as a statement about the category: there's currently no peer-reviewed number to put in the table above for compounded oral semaglutide or tirzepatide, positive or negative.
Bottom Line
- Want the single most effective option regardless of format? Injectable tirzepatide (SURMOUNT-1, 22.5%) still leads.
- Want to stay oral and get close to injectable-level results? High-dose oral semaglutide (OASIS 1/4) is the closest published match, not Rybelsus at its diabetes-indicated doses.
- Want oral without the SNAC dosing rules? Foundayo is a strong option, just not currently the top efficacy number in the category.
- Considering a compounded oral product? Go in knowing there's no published trial data for that specific route — see our compounded vs. FDA-approved explainer for what that actually means.